10-Q: XOMA Royalty Q3 2025: Strong Income Growth, Strategic Acquisitions

XOMA Royalty Corporation reports significant net income growth and strategic acquisitions in Q3 2025, driven by increased royalty and milestone payments.

Summary

• Net income for the three months ended September 30, 2025, was $14.1 million, a significant improvement from a net loss of $17.2 million for the same period in 2024.
• Net income for the nine months ended September 30, 2025, was $25.6 million, compared to a net loss of $9.9 million for the same period in 2024.
• Total income and revenues increased by $2.2 million to $9.4 million for Q3 2025 and by $18.6 million to $38.4 million for the nine months ended September 30, 2025, compared to the respective prior periods.
• Cash, cash equivalents, and restricted cash totaled $130.6 million as of September 30, 2025.
• Completed acquisitions of HilleVax and Turnstone in Q3 2025, recognizing bargain purchase gains of $17.9 million and $1.8 million, respectively.
• Earned a $5.0 million milestone payment from Rezolute as ersodetug (RZ358) dosed the last patient in its Phase 3 clinical trial.
• Acquired BioInvent's remaining rights to mezagitamab milestone and royalty payments for an upfront payment of $20.0 million, with a potential $10.0 million contingent payment upon FDA approval.
• Earned a $3.0 million milestone payment from Takeda as mezagitamab (TAK-079) dosed the first patient in its Phase 3 clinical trial.
• Entered into new At-The-Market (ATM) agreements in October 2025 with Leerink for common stock (up to $75.0 million) and with HCW for Series B Preferred Stock (up to $50.0 million).

Sentiment

Score: 8

Explanation: The company demonstrated a strong financial turnaround with significant net income and revenue growth, driven by successful royalty streams and strategic acquisitions that yielded bargain purchase gains. While cash balances decreased, the overall operational performance and future acquisition pipeline appear robust.

Positives

• Achieved a significant financial turnaround with net income of $14.1 million in Q3 2025, compared to a net loss of $17.2 million in Q3 2024.
• Reported strong year-to-date net income of $25.6 million for the nine months ended September 30, 2025, reversing a net loss of $9.9 million in the prior year period.
• Total income and revenues increased by $18.6 million to $38.4 million for the nine months ended September 30, 2025, demonstrating robust growth in royalty and commercial payment streams.
• Generated net cash of $8.4 million from operating activities for the nine months ended September 30, 2025, a substantial improvement from net cash used of $10.8 million in the prior year.
• Successfully completed strategic acquisitions of HilleVax and Turnstone, which resulted in bargain purchase gains of $17.9 million and $1.8 million, respectively.
• Achieved key clinical development milestones, including a $5.0 million payment from Rezolute for ersodetug (RZ358) and a $3.0 million payment from Takeda for mezagitamab (TAK-079), both advancing in Phase 3 trials.
• Fully paid all milestone obligations to Affitech under the Affitech CPPA, simplifying future payment structures.

Negatives

• Cash and cash equivalents decreased by $56.5 million, from $101.7 million as of December 31, 2024, to $45.2 million as of September 30, 2025.
• Working capital decreased by $18.8 million, from $101.2 million as of December 31, 2024, to $82.4 million as of September 30, 2025.
• Investment income decreased by $0.8 million for Q3 2025 and $2.5 million for the nine months ended September 30, 2025, primarily due to decreased cash balances.
• Recognized an unrealized loss of $3.9 million from the change in fair value of equity securities during the three months ended September 30, 2025.
• General and administrative expenses increased by $1.7 million for the three months ended September 30, 2025, primarily due to higher business development and deal-related costs.
• Incurred $2.4 million in common stock repurchases and an associated $24,000 excise tax during the nine months ended September 30, 2025.

Risks

• Results of operations and liquidity needs could be materially negatively affected by market fluctuations or an economic downturn, including as a result of tariff policies.
• Macroeconomic conditions such as inflation, recession, high interest rates, changes in trade policies (including tariffs), government shutdowns, and geopolitical instability could adversely affect the company, its licensees, or royalty-agreement counterparties.
• New U.S. tariffs, such as the announced plans to impose up to 100% tariffs on imported branded or patented pharmaceuticals, could have a material adverse effect on the business.
• Disruptions at the FDA and other government agencies (e.g., due to statutory/policy changes, inadequate funding, workforce reductions, or government shutdowns) could significantly impact the timely review and processing of regulatory submissions, negatively affecting product development and approval timelines.
• Uncertainty exists regarding the duration of existing tariffs, future tariff levels, and the potential for additional retaliatory actions by other countries.
• The presidential administration's potential leadership or policy changes at the FDA or other regulatory authorities could impact the company's business and operations or those of its royalty providers.

Future Outlook

The company expects most of its future income and revenue to be derived from milestone and royalty payments, along with periodic income recognition under the EIR method. Income from VABYSMO and OJEMDA royalties is projected to increase in future periods based on sales estimates. While significant Kinnate-related R&D costs are not anticipated, increased R&D costs may arise from contemplated acquisitions. The company believes its current financial resources are sufficient to fund planned operations and commitments for at least one year and may seek additional capital through new ATM agreements or other debt/equity transactions to support its expanding royalty portfolio.

Management Comments

• "Our royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase 1 and 2 development, which we believe have significant commercial sales potential and that are licensed to well-funded partners with established expertise in developing and commercializing drugs."
• "We also acquire milestone and royalty revenue streams on late-stage clinical assets and commercial assets that are designed to address unmet markets or have a therapeutic advantage over other treatment options, and have long duration of market exclusivity."
• "We expect most of our future revenue and income to be based on payments we may receive for milestones and royalties associated with these assets as well as the periodic recognition of income under the EIR method."
• "Based on our current cash balance and our planned discretionary spending, such as royalty or other acquisitions, we believe that our current financial resources are sufficient to fund our planned operations, commitments, and contractual obligations for a period of at least one year following the filing date of this Quarterly Report."
• "We may seek additional capital through our 2025 Common Stock ATM Agreement or our 2025 Series B Preferred Stock ATM Agreement... or through other public or private debt or equity transactions."

Industry Context

The company operates as a biotech royalty aggregator, a specialized business model that acquires economic rights to future payments from therapeutic candidates developed by other companies. This strategy allows for diversification across a portfolio of assets without direct involvement in costly R&D and commercialization. The focus on both early-to-mid-stage and late-stage/commercial assets reflects a balanced approach to risk and return in the pharmaceutical industry. The active acquisition strategy, exemplified by HilleVax and Turnstone, aligns with broader industry trends where companies seek to expand and optimize their intellectual property portfolios. The achievement of regulatory approvals and advancement of drugs into Phase 3 trials underscores the critical role of clinical development milestones in driving value in the biotech sector.

Corporate Governance

Legal Proceedings

• Not currently engaged in any legal proceedings that, in management's opinion, would individually or collectively have a material adverse effect on the business, results of operations, financial position, or cash flows.
• May become involved in litigation, arbitration, or other proceedings arising from the ordinary course of business in the future.
• Such matters are subject to significant uncertainties, and there is no assurance that any future legal proceedings will not have a material adverse effect on the business.

Related Party Transactions

• BVF (Biotechnology Value Fund, L.P.) owned approximately 21.0% of the Company's total outstanding common stock as of September 30, 2025, and would own 43.9% if all Series X Preferred Stock were converted, making BVF a related party.
• BVF owned approximately 24.7% of ESSA before its acquisition by Xeno, an acquisition that the Company facilitated and provided bridge financing for, and for which the Company received a $3.0 million arranger fee.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to strong financial performance, strategic acquisitions, and the ongoing stock repurchase program. However, new ATM agreements could lead to dilution.
• Employees: Benefits from stock-based compensation plans (stock options, PSUs, RSUs) and a specific cash-out arrangement for the CFO's stock options.
• Customers/Licensees: Continued development and commercialization of partnered therapeutic candidates (e.g., VABYSMO, OJEMDA, ersodetug, mezagitamab) benefits patients and partners through potential new treatments.
• Creditors: The Blue Owl Loan is being repaid as scheduled, indicating the company's ability to meet its debt obligations, which is positive for creditors.
• Acquired Companies (HilleVax, Turnstone, and planned LAVA, Mural): Shareholders of acquired entities receive cash and Contingent Value Rights (CVRs), while their assets are integrated into XOMA's royalty portfolio.

Next Steps

• Closing of the LAVA acquisition, with an adjusted tender offer price of $1.04 in cash per LAVA ordinary share plus one non-transferable CVR.
• Closing of the Mural acquisition, with a tender offer for a base cash price of $2.035 per Mural ordinary share and an additional cash amount up to $0.205 contingent upon Mural's closing net cash.
• Potential FDA approval of mezagitamab, which would trigger a $10.0 million contingent payment to BioInvent.
• Potential disposition (sale or licensing) of HIL-216, with CVR holders entitled to 90% of net proceeds if sold within two years of the HilleVax merger.
• Continued deployment of capital towards new royalty and milestone payment stream acquisitions.
• Potential future milestone payments to Dar of $11.0 million for each successive $22.0 million received under the Dar RPAs after achieving an $88.0 million return threshold.
• Continued common stock repurchases under the $50.0 million stock repurchase program, authorized through January 2027.
• Cash payments to Thomas Burns, CFO, in exchange for up to 142,278 vested stock options, on designated cash-out dates from February 18, 2026, to February 3, 2027.
• Funding an additional $0.8 million into the Blue Owl administrative fee escrow account on July 1, 2027.

Key Dates

Recommendation

The company has demonstrated a strong financial recovery and growth trajectory, moving from significant losses to profitability. Key drivers include increasing royalty and milestone income from commercialized and late-stage assets (VABYSMO, OJEMDA, ersodetug, mezagitamab) and successful strategic acquisitions (HilleVax, Turnstone) that generated substantial bargain purchase gains. The active pipeline of potential acquisitions (LAVA, Mural) and new ATM agreements position the company for continued expansion of its royalty portfolio. While cash balances decreased, the company maintains sufficient liquidity for its planned operations and commitments for at least one year. The overall outlook suggests a robust business model with strong execution, making it an attractive investment.

Keywords

Biotech royalty aggregator, Pharmaceutical royalties, Milestone payments, SEC filing, 10-Q, VABYSMO, OJEMDA, Mezagitamab, Ersodetug, HilleVax acquisition, Turnstone acquisition, Biotechnology, Drug development, Clinical trials, Corporate governance, Risk management, Capital raise